Evidence map›Paper›PMID 32206067›Full record

ReviewAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2020

CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy.

P Bégin, E S Chan, H Kim, M Wagner, M S Cellier, C Favron-Godbout, E M Abrams, M Ben-Shoshan, S B Cameron, S Carr and 7 more

Open access · goldAbstract readReview
In one paragraph

Review in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 4 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 4 syntheses or guidelines pooled it, 179 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pragmatic Low-Dose Oral Immunotherapy for Preschool Children With Peanut Allergy: A Randomised Controlled Trial.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025
    Trial
  6. Trial
  7. Dynamic regulation of CD300b and CD300f on myeloid cells in oral immunotherapy.The journal of allergy and clinical immunology. Global · 2026
    Article
  8. Predictive Biomarker for Persistent Food Allergy in Children.Allergy, asthma & immunology research · 2026
    Article
  9. Review
  10. Parent perspectives on guided self-care approaches to ensure timely access to therapy in infants with food allergy.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026
    Article
  11. Article
  12. The shift towards lower-risk oral food challenges since the implementation of oral immunotherapy: a retrospective cohort study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026
    Article
  13. Article
  14. Review
  15. Eating away at food allergy.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Review
  16. Article
  17. Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025
    Review
  18. Article
  19. Article
  20. Impact of oral immunotherapy on diversity of gut microbiota in food-allergic children.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 2 countries.

P Bégin1Division of Clinical Immunology, Rheumatology and Allergy, Department of Pediatrics, Sainte-Justine University Hospital Centre, Montreal, QC Canada.ORCID 0000-0002-9089-4604
E S Chan4Division of Allergy & Immunology, Department of Pediatrics, University of British Columbia, BC Children's Hospital, Vancouver, BC Canada.
H Kim5Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, ON Canada.
M Wagner7Unit Methods, Ethics and Participation, INESSS, National Institute for Excellence in Health and Social Services, Montreal, QC Canada.
M S Cellier3Research Center of the Sainte-Justine University Hospital Center, Montreal, QC Canada.
C Favron-Godbout8Department of Bioethics, School of Public Health of the University of Montreal, Montreal, Canada.
E M Abrams9Section of Allergy and Clinical Immunology, Department of Pediatrics, University of Manitoba, Winnipeg, MB Canada.
M Ben-Shoshan10Division of Allergy Immunology and Dermatology, Department of Pediatrics, Montreal Children's Hospital, Montreal, QC Canada.
S B Cameron4Division of Allergy & Immunology, Department of Pediatrics, University of British Columbia, BC Children's Hospital, Vancouver, BC Canada.
S Carr12Department of Pediatrics, University of Alberta, Edmonton, AB Canada.
D Fischer5Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, ON Canada.
A Haynes13Discipline of Pediatrics, Memorial University of Newfoundland, St. John's, NL Canada.
S Kapur14Department of Pediatrics, Dalhousie University, Halifax, NS Canada.
M N Primeau15Division of Allergy and Clinical Immunology, Department of Medicine, CISSS Laval, Laval, QC Canada.
J Upton16Division of Immunology and Allergy, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON Canada.
T K Vander Leek12Department of Pediatrics, University of Alberta, Edmonton, AB Canada.
M M Goetghebeur7Unit Methods, Ethics and Participation, INESSS, National Institute for Excellence in Health and Social Services, Montreal, QC Canada.
Centre Hospitalier Universitaire Sainte-Justine · CAInstitut National d'Excellence en Santé et en Services Sociaux · CAUniversity of Alberta · CAUniversity of British Columbia · CAWestern University · CACentre Intégré de Santé et de Services Sociaux des Laurentides · CADalhousie University · CAMemorial University of Newfoundland · CAMontreal Children's Hospital · CAUniversité de Montréal · CAUniversity of Manitoba · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral immunotherapy (OIT) is an emerging approach to the treatment of patients with IgE-mediated food allergy and is in the process of transitioning to clinical practice.

objectiveTo develop patient-oriented clinical practice guidelines on oral immunotherapy based on evidence and ethical imperatives for the provision of safe and efficient food allergy management. MATERIALS AND

methodsRecommendations were developed using a reflective patient-centered multicriteria approach including 22 criteria organized in five dimensions (clinical, populational, economic, organizational and sociopolitical). Data was obtained from: (1) a review of scientific and ethic literature; (2) consultations of allergists, other healthcare professionals (pediatricians, family physicians, nurses, registered dieticians, psychologists, peer supporters), patients and caregivers; and patient associations through structured consultative panels, interviews and on-line questionnaire; and (3) organizational and economic data from the milieu of care. All data was synthesized by criteria in a multicriteria deliberative guide that served as a platform for structured discussion and development of recommendations for each dimension, based on evidence, ethical imperatives and other considerations.

resultsThe deliberative grid included 162 articles from the literature and media reviews and data from consultations involving 85 individuals. Thirty-eight (38) recommendations were made for the practice of oral immunotherapy for the treatment of IgE mediated food allergy, based on evidence and a diversity of ethical imperatives. All recommendations were aimed at fostering a context conducive to achieving objectives identified by patients and caregivers with food allergy. Notably, specific recommendations were developed to promote a culture of shared responsibility between patients and healthcare system, equity in access, patient empowerment, shared decision making and personalization of OIT protocols to reflect patients' needs. It also provides recommendations to optimize organization of care to generate capacity to meet demand according to patient choice, e.g. OIT or avoidance. These recommendations were made acknowledging the necessity of ensuring sustainability of the clinical offer in light of various economic considerations.

conclusionsThis innovative CPG methodology was guided by patients' perspectives, clinical evidence as well as ethical and other rationales. This allowed for the creation of a broad set of recommendations that chart optimal clinical practice and define the conditions required to bring about changes to food allergy care that will be sustainable, equitable and conducive to the well-being of all patients in need.

Indexed as

AvoidanceClinical practice guidelinesContraindicationEthicsEvidenceFood allergyIndicationMulti-criteria decision analysisOral immunotherapyPatient-centeredQuality of life

Identifiers

PMID32206067
PMCPMC7079444
OpenAlexW3012931388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.